adlitterio66339

About adlitterio66339

This author has not yet filled in any details.
So far adlitterio66339 has created 715 blog entries.

1 04, 2024

Arsenal Sezgin Alikanoglu et al., Detection of High?Risk Human Papillomavirus (HPV) and Their Genotypes in Lung Cancer: Insights from the Mediterranean Region of Turkey

adlitterio663392024-10-07T09:12:52+02:00

23 03, 2024

Giulia Paesello et al., Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World

adlitterio663392024-03-23T12:42:34+01:00

22 03, 2024

Albino Eccher et al., Pathology Laboratory Archives: Conservation Quality of Nucleic Acids and Proteins for NSCLC Molecular Testing

adlitterio663392024-04-10T12:56:50+02:00

19 03, 2024

Marco Capezzone et al., Identification of a Novel Non-V600E BRAF Mutation in Papillary Thyroid Cancer

adlitterio663392024-03-19T12:51:12+01:00

16 03, 2024

Melchior Linea et al., Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC

adlitterio663392024-03-16T12:56:59+01:00

13 03, 2024

Shooting Cancer Highlights – Periodic focus on regulatory status of new targeted therapies in oncology

adlitterio663392024-03-15T15:53:41+01:00

27 02, 2024

Federica Di Maggio et al., A Novel DNA Variant in SMARCA4 Gene Found in a Patient Affected by Early Onset Colon Cancer

adlitterio663392024-02-27T14:15:40+01:00

20 02, 2024

Fabio Canino et al., Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients

adlitterio663392024-02-20T14:28:58+01:00

20 02, 2024

Zahra Abrehdari-Tafreshi et al., The Role of miR-29a and miR-143 on the Anti-apoptotic MCL-1/cIAP-2 Genes Expression in EGFR Mutated Non-small Cell Lung Carcinoma Patients

adlitterio663392024-04-10T14:21:40+02:00

14 02, 2024

Lorenza Rimassa et al., Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition

adlitterio663392024-02-14T14:34:18+01:00

Previous 678 Next